Respiratory Infections

The intranasal, live-attenuated vaccine CodaVax-RSV was granted FDA Fast Track designation. Clinical trials are expected to launch soon.

Vaccine efficacy of 81.8% was observed against severe medically attended lower respiratory tract illness due to respiratory syncytial virus (RSV) in infants from birth through the first 90 days of life.

Our cover story for the October 2022 print edition of Contagion details the original coronavirus.

The investigational vaccine was effective in reducing both lower respiratory tract and all respiratory tract infections.

Despite no significant reduction in time to discharge or recovery, inhalable SNG001 may lessen common symptoms of “long COVID.”

Ahead of the IDWeek 2022 conference, GSK shared data from their phase 3 RSV vaccine trial.

Before the emergence of COVID-19, this precursor virus was a global concern.

Articles covering respiratory infections were our most-clicked this week.

The Centers for Disease Control and Prevention (CDC) reports the rise in pediatric acute respiratory illnesses especially as there is a decrease in hygiene measures that were previously employed during the pandemic.

Pediatric populations are disproportionately affected by influenza. The first cell-based quadrivalent flu vaccine offers potential for greater vaccine effectiveness.

A recent study broke down hospitalizations associated with COVID-19 in adults between January 2021 and April of this year, based upon vaccination status.

The vaccine is meant to be administered during the third trimester of pregnancy to the expecting mother to prevent this respiratory disease in infants younger than 2 months of age.

These were our most popular articles this week. Catch up with these trending infectious disease stories.

The intervention included meeting with experts, texting services to improve and facilitate communication, and data collection and dissemination.

The CDC is urging all eligible persons to receive a flu shot, but a new survey shows fewer adults are planning to get the vaccine this season.

Catch up on Contagion's top stories from the month of September.

The federal agency recommends using either PCV13 or PCV15 as part of a 4-dose series for pediatric patients between the ages of 2-59 months.

Eravacycline is an antibiotic that has been touted for possible treatment of difficult-to-treat resistant (DTR) Gram-negative infections. But can it tackle carbapenem-resistant Acinetobacter baumannii (CRAB) infections?

Why do some children develop polio-like paralysis after contracting enterovirus? Here’s everything we know about the rare but increasing reports of acute flaccid myelitis.

COVID-19 viral load rebound occurred in 2.3% of nirmatrelvir–ritonavir (Paxlovid) recipients and in 1.7% of placebo recipients.

A new study found that patients hospitalized with COVID-19 are at significantly higher risk for venous thromboembolism in the ensuing 3 months than are patients hospitalized with influenza.

Pfizer-BioNTech and Moderna have developed new booster shots optimized for Omicron. They could be approved as soon as Labor Day.

From its results, the company plans to file a Biologics License Application (BLA) with the FDA.

The incubation period of the original, wild-type COVID-19 strain was 6.65 days, while the Omicron variant's incubation period has shortened to 3.42 days.

56% of adults with evidence of Omicron seropositivity did not know they were infected.